You are hereBlogs / admin's blog / Revisiting the ALA-N (alpha-lipoic acid - low-dose naltrexone) protocol for people with pancreatic cancer
Revisiting the ALA-N (alpha-lipoic acid - low-dose naltrexone) protocol for people with pancreatic cancer
Berkson BM, Rubin DM, Berkson AJ. Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther. 2009 Dec;8(4):416-22. Erratum in: Integr Cancer Ther. 2010 Jun;9(2):247. PubMed PMID: 20042414
After 4 months of the ALA/N protocol his PET scan demonstrated no signs of cancer. In this article, the authors discuss the poly activity of ALA: as an agent that reduces oxidative stress, its ability to stabilize NF(k)B, its ability to stimulate pro-oxidant apoptosic activity, and its discriminative ability to discourage the proliferation of malignant cells. In addition, the ability of low dose naltrexone to modulate an endogenous immune response is discussed.
Access to Parenteral Thiamine
Biological Therapies supplies a range of registered injections containing parenteral thiamine.
See the TGA website: http://www.tga.gov.au/safety/alerts-medicine-ivthiamine-100728.htm
See also the SHPA website: SHPA Manufacturers Alerts (Thiamine Injection)
